UroGen Pharma (URGN) is back on traders’ radar after new post hoc Phase 3 ENVISION data showed its bladder cancer candidate ZUSDURI delivered high, durable complete response rates across European risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results